The Efficacy of Adjuvant Chemotherapy in Locally Advanced Cervical Cancer

Prior treatment

• A history targeted therapy or pelvic artery embolization
• Complications, need to be treatment with drugs which may lead to liver or kidney injury

Other illness

• Activity or uncontrol severe infection
• Liver cirrhosis, Decompensated liver disease
• History of immune deficiency, including HIV positive or suffering from congenital immunodeficiency disease
• Patients who cannot tolerate chemotherapy because of chronic renal insufficiency or renal failure
• Have suffered or combined with other malignant tumor
• Myocardial infarction, severe arrhythmia and NYHA (New York heart association)≥2 for congestive heart failure
• Artery-enous thrombosis within 6 months
• Patients with autoimmune diseases
• Patients with disease progression after chemoradiation

• Cervical cancer stage IIb to IVa with histopathology of squamous cell carcinoma, adenosquamous cell carcinoma, adenocarcinoma
• Complete CCRT(Radiation Does: A point 85Gy(+/-10%)，B点50Gy(+/-10%)，concurrent platinum-containing chemotherapy (cisplatin or carboplatin))
• MRI is performed within 4 weeks after CCRT and shows residual lesions (non-lymph node≥10mm, lymph node shortest diameter≥15mm).
• ECOG\<2
• Expected survival is longer than six months
• Hb≥70g/L、WBC≥3.5×109/ L 、ANC≥1.5×109/L、PLT≥80×109/L
• ALT and AST≤2×ULN, Serum creatinine≤1.5×ULN
• The serum or urine pregnancy test must be negative within 7 days before enrollment for the women of childbearing age who should agree that contraception must be used during the trial